05Nov
BioFactura develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFastTM Biomanufacturing Platform, the optimal choice for bringing these drug to market with faster, lower cost, superior-quality manufacture.
The global biosimilars market is projected to grow from $24.2 billion in 2024 to $130.1 billion by 2035 with a Compound Annual Growth Rate of 20-25%. Key drivers of future growth include the significant market share enjoyed by first and second generation monoclonal antibodies and their continuing patent expiries. In addition, the global market seems highly favorable due to increasing pressure felt by countries of all development stages to control the spiraling costs of healthcare and provide access to lifesaving medicines to their populations. BioFactura has identified a niche in the biosimilars market with current innovator revenues of over $24 billion. These blockbuster targets are optimally suited for development employing the company’s StableFastTM technology.
BioFactura executed its first commercial biosimilar deal in 2013, completed a pivotal Phase 1 biosimilarity study for its lead asset, a biosimilar to the reference product Stelara, and has exclusively partnered that asset to Aurobindo/CuraTeQ to complete a Phase 3 trial and launch the product globally.